{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T16:56:12Z","timestamp":1783529772020,"version":"3.55.0"},"reference-count":211,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12035-025-05054-6","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T03:14:55Z","timestamp":1747365295000},"page":"14734-14762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Berberine can be a Potential Therapeutic Agent in Treatment of Huntington's Disease: A Proposed Mechanistic Insight"],"prefix":"10.1007","volume":"62","author":[{"given":"Seema","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderpreet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naina","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelima","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sampat Singh","family":"Tanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"3","key":"5054_CR1","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000524732","volume":"56","author":"A Exuzides","year":"2022","unstructured":"Exuzides A, Reddy SR, Chang E, Ta JT, Patel AM, Paydar C, Yohrling GJ (2022) Epidemiology of Huntington\u2019s disease in the United States medicare and medicaid populations. Neuroepidemiology 56(3):192\u2013200","journal-title":"Neuroepidemiology"},{"issue":"3\u20134","key":"5054_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000331912","volume":"37","author":"C Sackley","year":"2011","unstructured":"Sackley C, Hoppitt TJ, Calvert M, Gill P, Eaton B, Yao G, Pall H (2011) Huntington\u2019s disease: current epidemiology and pharmacological management in UK primary care. Neuroepidemiology 37(3\u20134):216\u2013221","journal-title":"Neuroepidemiology"},{"issue":"5","key":"5054_CR3","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000516767","volume":"55","author":"V Crowell","year":"2021","unstructured":"Crowell V, Houghton R, Tomar A, Fernandes T, Squitieri F (2021) Modeling manifest Huntington\u2019s disease prevalence using diagnosed incidence and survival time. Neuroepidemiology 55(5):361\u2013368","journal-title":"Neuroepidemiology"},{"issue":"4","key":"5054_CR4","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1159\/000319462","volume":"35","author":"YY Chen","year":"2010","unstructured":"Chen YY, Lai CH (2010) Nationwide population-based epidemiologic study of Huntington\u2019s disease in Taiwan. Neuroepidemiology 35(4):250\u2013254","journal-title":"Neuroepidemiology"},{"issue":"10","key":"5054_CR5","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1001\/jama.2023.13024","volume":"330","author":"R Marcus","year":"2023","unstructured":"Marcus R (2023) What is Huntington disease? JAMA 330(10):1014\u20131014","journal-title":"JAMA"},{"issue":"6","key":"5054_CR6","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.3174\/ajnr.A3772","volume":"35","author":"S Mahalingam","year":"2014","unstructured":"Mahalingam S, Levy LM (2014) Genetics of Huntington disease. Am J Neuroradiol 35(6):1070\u20131072","journal-title":"Am J Neuroradiol"},{"key":"5054_CR7","doi-asserted-by":"crossref","unstructured":"Sun X (2023, September) Diagnosis and treatment for Huntington\u2019s disease. In\u00a0International Conference on Modern Medicine and Global Health (ICMMGH 2023), SPIE, Vol. 12789, pp 154\u2013157","DOI":"10.1117\/12.2692222"},{"key":"5054_CR8","doi-asserted-by":"publisher","first-page":"106049","DOI":"10.1016\/j.parkreldis.2024.106049","volume":"122","author":"C Sampaio","year":"2024","unstructured":"Sampaio C (2024) Huntington disease\u2013Update on ongoing therapeutic developments and a look toward the future. Parkinsonism Relat Disord 122:106049","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"5054_CR9","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2174\/1570159X21666230216104621","volume":"21","author":"SA Bhat","year":"2023","unstructured":"Bhat SA, Ahamad S, Dar NJ, Siddique YH, Nazir A (2023) The emerging landscape of natural small-molecule therapeutics for Huntington\u2019s disease. Curr Neuropharmacol 21(4):867\u2013889","journal-title":"Curr Neuropharmacol"},{"key":"5054_CR10","doi-asserted-by":"publisher","unstructured":"Soko\u0142owska G, Jab\u0142o\u0144ska-Trypu\u0107 A, Naumowicz M (2024) Berberyna \u2013 zwi\u0105zek bioaktywny pozyskiwany z\u00a0ro\u015blin leczniczych. \u017bywno\u015b\u0107. Nauka. Technologia. Jako\u015b\u0107 31(3[140]):5\u201315.\u00a0https:\/\/doi.org\/10.15193\/zntj\/2024\/140\/506","DOI":"10.15193\/zntj\/2024\/140\/506"},{"key":"5054_CR11","doi-asserted-by":"publisher","unstructured":"Singh B, Katare AK (2020) Botanical sources, chemistry aspects and biological functions of berberine: an updated critical review. In: Botanical leads for drug discovery.\u00a0Elsevier, pp 421\u2013462. https:\/\/doi.org\/10.1016\/B978-0-12-817907-7.00015-3","DOI":"10.1016\/B978-0-12-817907-7.00015-3"},{"key":"5054_CR12","doi-asserted-by":"crossref","unstructured":"Mushtaq Z, Imran M, Saeed F, Imran A, Ali SW, Shahbaz M, ... , A Abdelgawad M (2023) Berberine: a comprehensive Approach to combat human maladies. Int J Food Properties 26(1):787\u2013807","DOI":"10.1080\/10942912.2023.2184300"},{"key":"5054_CR13","doi-asserted-by":"crossref","unstructured":"Murakami T, Bodor E, Bodor N (2023) Approaching strategy to increase the oral bioavailability of berberine, a quaternary ammonium isoquinoline alkaloid: Part 1. Physicochemical and pharmacokinetic properties. Expert Opin Drug Metab Toxicol 19(3):129\u2013137","DOI":"10.1080\/17425255.2023.2203857"},{"issue":"4","key":"5054_CR14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.2174\/0127724328250471231222094648","volume":"19","author":"C Coppinger","year":"2024","unstructured":"Coppinger C, Pomales B, Movahed MR, Marefat M, Hashemzadeh M (2024) Berberine: A multi-target natural PCSK9 inhibitor with the potential to treat diabetes, Alzheimer\u2019s, cancer and cardiovascular disease. Curr Rev Clin Exp Pharmacol Formerly Curr Clin Pharmacol 19(4):312\u2013326","journal-title":"Curr Rev Clin Exp Pharmacol Formerly Curr Clin Pharmacol"},{"issue":"11","key":"5054_CR15","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1002\/ptr.7589","volume":"36","author":"A Khoshandam","year":"2022","unstructured":"Khoshandam A, Imenshahidi M, Hosseinzadeh H (2022) Pharmacokinetic of berberine, the main constituent of Berberis vulgaris L.: a comprehensive review. Phytotherapy Res 36(11):4063\u20134079","journal-title":"Phytotherapy Res"},{"issue":"3","key":"5054_CR16","doi-asserted-by":"publisher","first-page":"100070","DOI":"10.1016\/j.phyplu.2021.100070","volume":"1","author":"P Patel","year":"2021","unstructured":"Patel P (2021) A bird\u2019s eye view on a therapeutically \u2018wonder molecule\u2019: Berberine. Phytomedicine plus 1(3):100070","journal-title":"Phytomedicine plus"},{"key":"5054_CR17","doi-asserted-by":"crossref","unstructured":"Handsaker RE, Kashin S, Reed NM, Tan S, Lee WS, McDonald TM, ..., McCarroll SA (2025) Long somatic DNA-repeat expansion drives neurodegeneration in Huntington\u2019s disease. Cell 188(3):623\u2013639","DOI":"10.1016\/j.cell.2024.11.038"},{"key":"5054_CR18","doi-asserted-by":"crossref","unstructured":"Landles C, Osborne GF, Phillips J, Canibano-Pico M, Nita IM, Ali N, ... Bates GP (2024) Mutant huntingtin protein decreases with CAG repeat expansion: implications for therapeutics and bioassays. Brain Commun 6(6):fcae410","DOI":"10.1093\/braincomms\/fcae410"},{"key":"5054_CR19","doi-asserted-by":"crossref","unstructured":"Tong H, Yang T, Xu S, Li X, Liu L, Zhou G, ..., Li S (2024) Huntington\u2019s disease: complex pathogenesis and therapeutic strategies. Int J Mol Sci 25(7):3845","DOI":"10.3390\/ijms25073845"},{"issue":"16","key":"5054_CR20","doi-asserted-by":"publisher","first-page":"13021","DOI":"10.3390\/ijms241613021","volume":"24","author":"A Jiang","year":"2023","unstructured":"Jiang A, Handley RR, Lehnert K, Snell RG (2023) From pathogenesis to therapeutics: a review of 150 years of Huntington\u2019s disease research. Int J Mol Sci 24(16):13021","journal-title":"Int J Mol Sci"},{"key":"5054_CR21","doi-asserted-by":"publisher","first-page":"100056","DOI":"10.1016\/j.prdoa.2020.100056","volume":"3","author":"EM Gatto","year":"2020","unstructured":"Gatto EM, Rojas NG, Persi G, Etcheverry JL, Cesarini ME, Perandones C (2020) Huntington disease: advances in the understanding of its mechanisms. Clin Parkinsonism Related Disord 3:100056","journal-title":"Clin Parkinsonism Related Disord"},{"issue":"3","key":"5054_CR22","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1566-2772(03)00054-9","volume":"3","author":"LA Raymond","year":"2003","unstructured":"Raymond LA (2003) Excitotoxicity in Huntington disease. Clin Neurosci Res 3(3):121\u2013128","journal-title":"Clin Neurosci Res"},{"issue":"2","key":"5054_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41418-020-00667-x","volume":"28","author":"F Le Guerrou\u00e9","year":"2021","unstructured":"Le Guerrou\u00e9 F, Youle RJ (2021) Ubiquitin signaling in neurodegenerative diseases: an autophagy and proteasome perspective. Cell Death Differ 28(2):439\u2013454","journal-title":"Cell Death Differ"},{"issue":"6","key":"5054_CR24","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.2174\/1570159X19666211201094608","volume":"20","author":"J Saba","year":"2022","unstructured":"Saba J, Couselo FL, Bruno J, Carniglia L, Durand D, Lasaga M, Caruso C (2022) Neuroinflammation in Huntington\u2019s disease: a starring role for astrocyte and microglia. Curr Neuropharmacol 20(6):1116\u20131143","journal-title":"Curr Neuropharmacol"},{"issue":"11","key":"5054_CR25","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/ptr.5693","volume":"30","author":"M Imenshahidi","year":"2016","unstructured":"Imenshahidi M, Hosseinzadeh H (2016) Berberis vulgaris and berberine: an update review. Phytother Res 30(11):1745\u20131764","journal-title":"Phytother Res"},{"key":"5054_CR26","unstructured":"Prajwala B, Raghu N, Gopenath TS, Shanmukhappa B, Karthikeyan M, Ashok G, ..., Kanthesh MB (2020) Berberine and its pharmacology potential: a review. Eur J Biomed 7(5):115\u201323"},{"key":"5054_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ejphar.2015.05.068","volume":"761","author":"A Kumar","year":"2015","unstructured":"Kumar A, Chopra K, Mukherjee M, Pottabathini R, Dhull DK (2015) Current knowledge and pharmacological profile of berberine: an update. Eur J Pharmacol 761:288\u2013297","journal-title":"Eur J Pharmacol"},{"key":"5054_CR28","first-page":"64","volume":"3","author":"A Singh","year":"2010","unstructured":"Singh A, Duggal S, Kaur N, Singh J (2010) Berberine: alkaloid with wide spectrum of pharmacological activities. J Nat Prod (India) 3:64\u201375","journal-title":"J Nat Prod (India)"},{"issue":"7","key":"5054_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3390\/biology12070973","volume":"12","author":"AR Utami","year":"2023","unstructured":"Utami AR, Maksum IP, Deawati Y (2023) Berberine and its study as an antidiabetic compound. Biology 12(7):973","journal-title":"Biology"},{"key":"5054_CR30","doi-asserted-by":"crossref","unstructured":"Joshi T, Singh AK, Haratipour P, Sah AN, Pandey AK, Naseri R, ..., Farzaei MH (2019) Targeting AMPK signaling pathway by natural products for treatment of diabetes mellitus and its complications. J Cell Physiol 234(10):17212\u201317231","DOI":"10.1002\/jcp.28528"},{"key":"5054_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/B978-0-12-817907-9.00003-9","volume":"66","author":"JM Germ\u00e1n-Acacio","year":"2020","unstructured":"Germ\u00e1n-Acacio JM, Meza-S\u00e1nchez DE, Morales-Morales D (2020) Therapeutically relevant natural products as AMPK activators in the treatment of diabetes. Stud Nat Prod Chem 66:57\u201390","journal-title":"Stud Nat Prod Chem"},{"key":"5054_CR32","doi-asserted-by":"publisher","first-page":"1187718","DOI":"10.3389\/fnut.2023.1187718","volume":"10","author":"F Yang","year":"2023","unstructured":"Yang F, Gao R, Luo X, Liu R, Xiong D (2023) Berberine influences multiple diseases by modifying gut microbiota. Front Nutr 10:1187718","journal-title":"Front Nutr"},{"key":"5054_CR33","doi-asserted-by":"crossref","unstructured":"Araj-Khodaei M, Ayati MH, Azizi Zeinalhajlou A, Novinbahador T, Yousefi M, Shiri M, ..., Sanaie S (2024) Berberine-induced glucagon-like peptide-1 and its mechanism for controlling type 2 diabetes mellitus: a comprehensive pathway review. Arch Physiol Biochem 130(6):678\u2013685","DOI":"10.1080\/13813455.2023.2258559"},{"issue":"3","key":"5054_CR34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1527-3466.2001.tb00068.x","volume":"19","author":"CW Lau","year":"2001","unstructured":"Lau CW, Yao XQ, Chen ZY, Ko WH, Huang Y (2001) Cardiovascular actions of berberine. Cardiovasc Drug Rev 19(3):234\u2013244","journal-title":"Cardiovasc Drug Rev"},{"issue":"6","key":"5054_CR35","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s40495-016-0070-1","volume":"2","author":"M Zhang","year":"2016","unstructured":"Zhang M, Feng L, Li J, Chen L (2016) Therapeutic potential and mechanisms of berberine in cardiovascular disease. Current Pharmacology Reports 2(6):281\u2013292","journal-title":"Current Pharmacology Reports"},{"key":"5054_CR36","doi-asserted-by":"publisher","first-page":"103666","DOI":"10.1016\/j.jprot.2020.103666","volume":"215","author":"GF Du","year":"2020","unstructured":"Du GF, Le YJ, Sun X, Yang XY, He QY (2020) Proteomic investigation into the action mechanism of berberine against Streptococcus pyogenes. J Proteomics 215:103666","journal-title":"J Proteomics"},{"key":"5054_CR37","doi-asserted-by":"crossref","unstructured":"Chu M, Ding R, Chu ZY, Zhang MB, Liu XY, Xie SH, ..., Wang YD (2014) Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4\/MD-2 receptor. BMC Complement Alternat Med 14:1\u20139","DOI":"10.1186\/1472-6882-14-89"},{"key":"5054_CR38","doi-asserted-by":"crossref","unstructured":"Zha W, Liang G, Xiao J, Studer EJ, Hylemon PB, Pandak Jr WM, ..., Zhou H (2010) Berberine inhibits HIV protease inhibitor-induced inflammatory response by modulating ER stress signaling pathways in murine macrophages. PLoS One 5(2):e9069","DOI":"10.1371\/journal.pone.0009069"},{"issue":"1","key":"5054_CR39","first-page":"9970240","volume":"2021","author":"Y Jiang","year":"2021","unstructured":"Jiang Y, Zhao L, Chen Q, Zhou L (2021) Exploring the mechanism of berberine intervention in ulcerative colitis from the perspective of inflammation and immunity based on systemic pharmacology. Evid-Based Complement Alternat Med 2021(1):9970240","journal-title":"Evid-Based Complement Alternat Med"},{"issue":"21","key":"5054_CR40","doi-asserted-by":"publisher","first-page":"12234","DOI":"10.1111\/jcmm.15803","volume":"24","author":"P Shen","year":"2020","unstructured":"Shen P, Jiao Y, Miao L, Chen JH, Momtazi-Borojeni AA (2020) Immunomodulatory effects of berberine on the inflamed joint reveal new therapeutic targets for rheumatoid arthritis management. J Cell Mol Med 24(21):12234\u201312245","journal-title":"J Cell Mol Med"},{"key":"5054_CR41","doi-asserted-by":"publisher","first-page":"105667","DOI":"10.1016\/j.phrs.2021.105667","volume":"169","author":"DN Huang","year":"2021","unstructured":"Huang DN, Wu FF, Zhang AH, Sun H, Wang XJ (2021) Efficacy of berberine in treatment of rheumatoid arthritis: From multiple targets to therapeutic potential. Pharmacol Res 169:105667","journal-title":"Pharmacol Res"},{"issue":"9","key":"5054_CR42","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.4314\/tjpr.v21i9.2","volume":"21","author":"D Gao","year":"2022","unstructured":"Gao D, Liu Y (2022) Berberine regulates endocrine function in mice with polycystic ovary syndrome through PI3K\/Akt\/GSK-3\u03b2 insulin signaling pathway. Trop J Pharm Res 21(9):1823\u20131828","journal-title":"Trop J Pharm Res"},{"key":"5054_CR43","doi-asserted-by":"publisher","first-page":"153654","DOI":"10.1016\/j.phymed.2021.153654","volume":"91","author":"Z Wang","year":"2021","unstructured":"Wang Z, Nie K, Su H, Tang Y, Wang H, Xu X, Dong H (2021) Berberine improves ovulation and endometrial receptivity in polycystic ovary syndrome. Phytomedicine 91:153654","journal-title":"Phytomedicine"},{"key":"5054_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12958-020-00684-y","volume":"19","author":"HR Shen","year":"2021","unstructured":"Shen HR, Xu X, Li XL (2021) Berberine exerts a protective effect on rats with polycystic ovary syndrome by inhibiting the inflammatory response and cell apoptosis. Reprod Biol Endocrinol 19:1\u201311","journal-title":"Reprod Biol Endocrinol"},{"key":"5054_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12865-020-00358-9","volume":"21","author":"Z Lu","year":"2020","unstructured":"Lu Z, He B, Chen Z, Yan M, Wu L (2020) Anti-inflammatory activity of berberine in non-alcoholic fatty liver disease via the Angptl2 pathway. BMC Immunol 21:1\u20139","journal-title":"BMC Immunol"},{"key":"5054_CR46","doi-asserted-by":"crossref","unstructured":"Ren S, Ma X, Wang R, Liu H, Wei Y, Wei S, ..., Zhao Y (2021) Preclinical evidence of berberine on non-alcoholic fatty liver disease: a systematic review and meta-analysis of animal studies.\u00a0Front Pharmacol 12:742465","DOI":"10.3389\/fphar.2021.742465"},{"key":"5054_CR47","doi-asserted-by":"crossref","unstructured":"Ionita-Radu F, Patoni C, Nancoff AS, Marin FS, Gaman L, Bucurica A, ..., Bucurica S (2024) Berberine effects in pre-fibrotic stages of non-alcoholic fatty liver disease\u2014Clinical and pre-clinical overview and systematic review of the literature. Int J Mol Sci 25(8):4201","DOI":"10.3390\/ijms25084201"},{"issue":"8","key":"5054_CR48","doi-asserted-by":"publisher","first-page":"6732","DOI":"10.3390\/molecules16086732","volume":"16","author":"HF Ji","year":"2011","unstructured":"Ji HF, Shen L (2011) Berberine: a potential multipotent natural product to combat Alzheimer\u2019s disease. Molecules 16(8):6732\u20136740","journal-title":"Molecules"},{"key":"5054_CR49","doi-asserted-by":"crossref","unstructured":"Dan L, Hao Y, Li J, Wang T, Zhao W, Wang H, ..., Xie P (2024) Neuroprotective effects and possible mechanisms of berberine in animal models of Alzheimer\u2019s disease: a systematic review and meta-analysis. Front Pharmacol 14:1287750","DOI":"10.3389\/fphar.2023.1287750"},{"key":"5054_CR50","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2147\/CMAR.S246361","volume":"12","author":"Y Wang","year":"2020","unstructured":"Wang Y, Liu Y, Du X, Ma H, Yao J (2020) The anti-cancer mechanisms of berberine: a review. Cancer Manag Res 12:695\u2013702. https:\/\/doi.org\/10.2147\/CMAR.S246361","journal-title":"Cancer Manag Res"},{"key":"5054_CR51","doi-asserted-by":"crossref","unstructured":"Zhu Y, Xie N, Chai Y, Nie Y, Liu K, Liu Y, ..., Zhang C (2022) Apoptosis induction, a sharp edge of berberine to exert anti-cancer effects, focus on breast, lung, and liver cancer.\u00a0Front Pharmacol 13:803717","DOI":"10.3389\/fphar.2022.803717"},{"key":"5054_CR52","doi-asserted-by":"crossref","unstructured":"Xiong RG, Huang SY, Wu SX, Zhou DD, Yang ZJ, Saimaiti A, ..., Li HB (2022) Anticancer effects and mechanisms of berberine from medicinal herbs: an update review.\u00a0Molecules 27(14):4523","DOI":"10.3390\/molecules27144523"},{"key":"5054_CR53","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.ejphar.2014.06.025","volume":"740","author":"PJ Kaboli","year":"2014","unstructured":"Kaboli PJ, Rahmat A, Ismail P, Ling KH (2014) Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer. Eur J Pharmacol 740:584\u2013595","journal-title":"Eur J Pharmacol"},{"key":"5054_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fphar.2019.00009","volume":"10","author":"D Liu","year":"2019","unstructured":"Liu D, Meng X, Wu D, Qiu Z, Luo H (2019) A natural isoquinoline alkaloid with antitumor activity: studies of the biological activities of berberine. Front Pharmacol 10:9","journal-title":"Front Pharmacol"},{"key":"5054_CR55","doi-asserted-by":"crossref","unstructured":"Behl T, Singh S, Sharma N, Zahoor I, Albarrati A, Albratty M, ..., Bungau S (2022) Expatiating the pharmacological and nanotechnological aspects of the alkaloidal drug berberine: current and future trends.\u00a0Molecules 27(12):3705","DOI":"10.3390\/molecules27123705"},{"issue":"6","key":"5054_CR56","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3390\/brainsci14060596","volume":"14","author":"HC Tseng","year":"2024","unstructured":"Tseng HC, Wang MH, Fang CH, Lin YW, Soung HS (2024) Neuroprotective potentials of berberine in rotenone-induced parkinson\u2019s disease-like motor symptoms in rats. Brain Sci 14(6):596","journal-title":"Brain Sci"},{"issue":"3","key":"5054_CR57","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/tkm2.1431","volume":"11","author":"D Mehboodi","year":"2024","unstructured":"Mehboodi D, Shahedi A, Namavar M, Yadegari M, Mazaheri F (2024) Berberine alleviates cerebellar damage in global cerebral ischemia: a comprehensive study with stereological analysis, evaluation of the antioxidant response, and locomotor function in rat models. Traditional & Kampo Medicine 11(3):222\u2013229","journal-title":"Traditional & Kampo Medicine"},{"issue":"11","key":"5054_CR58","first-page":"43","volume":"7","author":"AM Mahmoud","year":"2017","unstructured":"Mahmoud AM, Fadel A, Ramadan SM, Hozayen WG (2017) Berberine mitigates methotrexate-induced oxidative stress and inflammation in the cerebrum of rats. J Appl Pharm Sci 7(11):43\u201349","journal-title":"J Appl Pharm Sci"},{"key":"5054_CR59","doi-asserted-by":"crossref","unstructured":"Zhang C, Li C, Chen S, Li Z, Jia X, Wang K, ... He C (2017) Berberine protects against 6-OHDA-induced neurotoxicity in PC12 cells and zebrafish through hormetic mechanisms involving PI3K\/AKT\/Bcl-2 and Nrf2\/HO-1 pathways.\u00a0Redox Boil 11:1\u201311.","DOI":"10.1016\/j.redox.2016.10.019"},{"key":"5054_CR60","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.neuro.2022.01.011","volume":"89","author":"A Yardim","year":"2022","unstructured":"Yardim A, Gur C, Comakli S, Ozdemir S, Kucukler S, Celik H, Kandemir FM (2022) Investigation of the effects of berberine on bortezomib-induced sciatic nerve and spinal cord damage in rats through pathways involved in oxidative stress and neuro-inflammation. Neurotoxicology 89:127\u2013139","journal-title":"Neurotoxicology"},{"key":"5054_CR61","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.phrs.2007.06.003","volume":"56","author":"CH, L.","year":"2007","unstructured":"CH, L. (2007) Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. Pharmacol Res 56:193\u2013201","journal-title":"Pharmacol Res"},{"key":"5054_CR62","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.brainresbull.2017.08.008","volume":"134","author":"YM Liu","year":"2017","unstructured":"Liu YM, Niu L, Wang LL, Bai L, Fang XY, Li YC, Yi LT (2017) Berberine attenuates depressive-like behaviors by suppressing neuro-inflammation in stressed mice. Brain Res Bull 134:220\u2013227","journal-title":"Brain Res Bull"},{"key":"5054_CR63","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.intimp.2016.06.031","volume":"38","author":"Z Zhang","year":"2016","unstructured":"Zhang Z, Li X, Li F, An L (2016) Berberine alleviates postoperative cognitive dysfunction by suppressing neuroinflammation in aged mice. Int Immunopharmacol 38:426\u2013433","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"5054_CR64","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/jcb.22580","volume":"110","author":"DY Lu","year":"2010","unstructured":"Lu DY, Tang CH, Chen YH, Wei IH (2010) Berberine suppresses neuroinflammatory responses through AMP-activated protein kinase activation in BV-2 microglia. J Cell Biochem 110(3):697\u2013705","journal-title":"J Cell Biochem"},{"issue":"1","key":"5054_CR65","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.foodchem.2011.10.065","volume":"132","author":"WH Chueh","year":"2012","unstructured":"Chueh WH, Lin JY (2012) Berberine, an isoquinoline alkaloid, inhibits streptozotocin-induced apoptosis in mouse pancreatic islets through down-regulating Bax\/Bcl-2 gene expression ratio. Food Chem 132(1):252\u2013260","journal-title":"Food Chem"},{"key":"5054_CR66","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.neulet.2017.06.048","volume":"655","author":"Y Liang","year":"2017","unstructured":"Liang Y, Huang M, Jiang X, Liu Q, Chang X, Guo Y (2017) The neuroprotective effects of Berberine against amyloid \u03b2-protein-induced apoptosis in primary cultured hippocampal neurons via mitochondria-related caspase pathway. Neurosci Lett 655:46\u201353","journal-title":"Neurosci Lett"},{"issue":"3","key":"5054_CR67","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1556\/APhysiol.99.2012.3.8","volume":"99","author":"Q Zhang","year":"2012","unstructured":"Zhang Q, Qian Z, Pan L, Li H, Zhu H (2012) Hypoxia-inducible factor 1 mediates the anti-apoptosis of berberine in neurons during hypoxia\/ischemia. Acta Physiol Hung 99(3):311\u2013323","journal-title":"Acta Physiol Hung"},{"key":"5054_CR68","doi-asserted-by":"crossref","unstructured":"Li W, Liu Y, Wang B, Luo Y, Hu N, Chen D, ... Xiong Y (2016) Protective effect of berberine against oxidative stress-induced apoptosis in rat bone marrow-derived mesenchymal stem cells.\u00a0Exp Therapeutic Med 12(6):4041\u20134048","DOI":"10.3892\/etm.2016.3866"},{"key":"5054_CR69","doi-asserted-by":"crossref","unstructured":"Liu YL, Guo T, Zhang YJ, Tang SC, Zhao XM, He HY, ... Deng YH (2024) Berberine alleviates ischemic brain injury by enhancing autophagic flux via facilitation of TFEB nuclear translocation.\u00a0The Am J Chin Med 52(01):231\u2013252","DOI":"10.1142\/S0192415X24500101"},{"issue":"2","key":"5054_CR70","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/cells10020333","volume":"10","author":"M Chen","year":"2021","unstructured":"Chen M, Dai Y, Liu S, Fan Y, Ding Z, Li D (2021) TFEB biology and agonists at a glance. Cells 10(2):333","journal-title":"Cells"},{"key":"5054_CR71","doi-asserted-by":"crossref","unstructured":"Zheng Y, Kou J, Wang P, Ye T, Wang Z, Gao Z, ... Yang L (2021) Berberine-induced TFEB deacetylation by SIRT1 promotes autophagy in peritoneal macrophages. Aging (Albany NY) 13(5):7096","DOI":"10.18632\/aging.202566"},{"key":"5054_CR72","doi-asserted-by":"publisher","first-page":"119078","DOI":"10.1016\/j.lfs.2021.119078","volume":"269","author":"FH Shaker","year":"2021","unstructured":"Shaker FH, El-Derany MO, Wahdan SA, El-Demerdash E, El-Mesallamy HO (2021) Berberine ameliorates doxorubicin-induced cognitive impairment (chemobrain) in rats. Life Sci 269:119078","journal-title":"Life Sci"},{"issue":"5","key":"5054_CR73","first-page":"580","volume":"9","author":"SD Kuipers","year":"2006","unstructured":"Kuipers SD, Bramham CR (2006) Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Curr Opin Drug Discov Devel 9(5):580","journal-title":"Curr Opin Drug Discov Devel"},{"issue":"1","key":"5054_CR74","first-page":"23","volume":"26","author":"F Mohseni","year":"2023","unstructured":"Mohseni F, Rafaiee R, Rezaeian L, Sarvandani MN, Moghaddam HK (2023) Berberine hydrochloride improves cognitive deficiency through hippocampal up-regulation of neurotrophins following inhalant self-administration of methamphetamine. Iran J Basic Med Sci 26(1):23","journal-title":"Iran J Basic Med Sci"},{"issue":"6","key":"5054_CR75","doi-asserted-by":"publisher","first-page":"983","DOI":"10.4103\/1673-5374.233438","volume":"13","author":"S Habtemariam","year":"2018","unstructured":"Habtemariam S (2018) The brain-derived neurotrophic factor in neuronal plasticity and neuroregeneration: new pharmacological concepts for old and new drugs. Neural Regen Res 13(6):983\u2013984","journal-title":"Neural Regen Res"},{"key":"5054_CR76","doi-asserted-by":"crossref","unstructured":"Wen HY, Pan LB, Ma SR, Yang XY, Hu JC, Zhao HF, ..., Zhang H (2022) Structural basis for the transformation of the traditional medicine berberine by bacterial nitroreductase. Biol Crystallogr 78(10):1273\u20131282","DOI":"10.1107\/S2059798322008373"},{"key":"5054_CR77","doi-asserted-by":"publisher","first-page":"1281090","DOI":"10.3389\/fphar.2023.1281090","volume":"14","author":"T Dehau","year":"2023","unstructured":"Dehau T, Cherlet M, Croubels S, Van De Vliet M, Goossens E, Van Immerseel F (2023) Berberine-microbiota interplay: orchestrating gut health through modulation of the gut microbiota and metabolic transformation into bioactive metabolites. Front Pharmacol 14:1281090","journal-title":"Front Pharmacol"},{"key":"5054_CR78","doi-asserted-by":"crossref","unstructured":"Duan H, Hu J, Deng Y, Zou J, Ding W, Peng Q, ... Zhu J (2023) Berberine mediates the production of butyrate to ameliorate cerebral ischemia via the gut microbiota in mice.\u00a0Nutrients 16(1):9","DOI":"10.3390\/nu16010009"},{"issue":"10","key":"5054_CR79","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.3390\/antiox12101883","volume":"12","author":"E Tian","year":"2023","unstructured":"Tian E, Sharma G, Dai C (2023) Neuroprotective properties of berberine: molecular mechanisms and clinical implications. Antioxidants 12(10):1883","journal-title":"Antioxidants"},{"key":"5054_CR80","doi-asserted-by":"publisher","first-page":"155624","DOI":"10.1016\/j.phymed.2024.155624","volume":"129","author":"C Sun","year":"2024","unstructured":"Sun C, Dong S, Chen W, Li J, Luo E, Ji J (2024) Berberine alleviates Alzheimer\u2019s disease by regulating the gut microenvironment, restoring the gut barrier and brain-gut axis balance. Phytomedicine 129:155624","journal-title":"Phytomedicine"},{"key":"5054_CR81","doi-asserted-by":"crossref","unstructured":"Ge PY, Qu SY, Ni SJ, Yao ZY, Qi YY, Zhao X, ... Zhu HX (2023) Berberine ameliorates depression\u2010like behavior in CUMS mice by activating TPH1 and inhibiting IDO1\u2010associated with tryptophan metabolism.\u00a0Phytother Res 37(1):342\u2013357","DOI":"10.1002\/ptr.7616"},{"issue":"10","key":"5054_CR82","doi-asserted-by":"publisher","first-page":"e23434","DOI":"10.1002\/jbt.23434","volume":"37","author":"A Phogat","year":"2023","unstructured":"Phogat A, Singh J, Malik V, Kumar V (2023) Neuroprotective potential of berberine against acetamiprid induced toxicity in rats: Implication of oxidative stress, mitochondrial alterations, and structural changes in brain regions. J Biochem Mol Toxicol 37(10):e23434","journal-title":"J Biochem Mol Toxicol"},{"issue":"1","key":"5054_CR83","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/ijms25010219","volume":"25","author":"JH Um","year":"2023","unstructured":"Um JH, Lee KM, Kim YY, Lee DY, Kim E, Kim DH, Yun J (2023) Berberine induces mitophagy through adenosine monophosphate-activated protein kinase and ameliorates mitochondrial dysfunction in PINK1 knockout mouse embryonic fibroblasts. Int J Mol Sci 25(1):219","journal-title":"Int J Mol Sci"},{"issue":"2","key":"5054_CR84","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3390\/ijms24020903","volume":"24","author":"I Hori","year":"2023","unstructured":"Hori I, Harashima H, Yamada Y (2023) Development of a mitochondrial targeting lipid nanoparticle encapsulating berberine. Int J Mol Sci 24(2):903","journal-title":"Int J Mol Sci"},{"issue":"1","key":"5054_CR85","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/WNR.0000000000001365","volume":"31","author":"H Deng","year":"2020","unstructured":"Deng H, Jia Y, Pan D, Ma Z (2020) Berberine alleviates rotenone-induced cytotoxicity by antioxidation and activation of PI3K\/Akt signaling pathway in SH-SY5Y cells. NeuroReport 31(1):41\u201347","journal-title":"NeuroReport"},{"key":"5054_CR86","doi-asserted-by":"publisher","first-page":"2412311","DOI":"10.1002\/advs.202412311","volume":"12","author":"H Zhao","year":"2025","unstructured":"Zhao H, Chen S, Cao N, Wu W, Liu G, Gao J, Chen J, Li T et al (2025) Berberine is a novel mitochondrial calcium uniporter inhibitor that disrupts MCU-EMRE assembly. Adv Sci 12:2412311","journal-title":"Adv Sci"},{"key":"5054_CR87","doi-asserted-by":"publisher","first-page":"7593608","DOI":"10.1155\/2019\/7593608","volume":"2019","author":"C Zhao","year":"2019","unstructured":"Zhao C, Su P, Lv C, Guo L, Cao G, Qin C, Zhang W (2019) Berberine alleviates amyloid \u03b2-induced mitochondrial dysfunction and synaptic loss. Oxid Med Cell Longev 2019:7593608. https:\/\/doi.org\/10.1155\/2019\/7593608","journal-title":"Oxid Med Cell Longev"},{"key":"5054_CR88","doi-asserted-by":"publisher","first-page":"640758","DOI":"10.3389\/fphar.2021.640758","volume":"12","author":"Y Wu","year":"2021","unstructured":"Wu Y, Chen Q, Wen B, Wu N, He B, Chen J (2021) Berberine reduces A\u03b242 deposition and tau hyperphosphorylation via ameliorating endoplasmic reticulum stress. Front Pharmacol 12:640758","journal-title":"Front Pharmacol"},{"key":"5054_CR89","doi-asserted-by":"crossref","unstructured":"Zhao L, Li H, Gao Q, Xu J, Zhu Y, Zhai M, ... Liu C (2021) Berberine attenuates cerebral ischemia-reperfusion injury induced neuronal apoptosis by down-regulating the CNPY2 signaling pathway.\u00a0Front Pharmacol 12:609693.","DOI":"10.3389\/fphar.2021.609693"},{"issue":"6","key":"5054_CR90","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1007\/s11596-020-2286-x","volume":"40","author":"P Xie","year":"2020","unstructured":"Xie P, Ren ZK, Lv J, Hu YM, Guan ZZ, Yu WF (2020) Berberine ameliorates oxygen-glucose deprivation\/reperfusion-induced apoptosis by inhibiting endoplasmic reticulum stress and autophagy in PC12 cells. Current medical science 40(6):1047\u20131056","journal-title":"Current medical science"},{"key":"5054_CR91","doi-asserted-by":"crossref","unstructured":"Li HY, Wang XC, Xu YM, Luo NC, Luo S, Hao XY, ... Chen YB (2018) Berberine improves diabetic encephalopathy through the SIRT1\/ER stress pathway in db\/db mice.\u00a0Rejuvenation Res 21(3):200\u2013209.","DOI":"10.1089\/rej.2017.1972"},{"issue":"5","key":"5054_CR92","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1089\/rej.2022.0023","volume":"25","author":"N Chen","year":"2022","unstructured":"Chen N, Wang XC, Fan LL, Zhu YH, Wang Q, Chen YB (2022) Berberine ameliorates lipopolysaccharide-induced cognitive impairment through SIRT1\/NRF2\/NF-\u03baB signaling pathway in C57BL\/6J Mice. Rejuvenation Res 25(5):233\u2013242","journal-title":"Rejuvenation Res"},{"issue":"11","key":"5054_CR93","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2174\/1567205015666180702105740","volume":"15","author":"Z Cai","year":"2018","unstructured":"Cai Z, Wang C, He W, Chen Y (2018) Berberine alleviates amyloid-beta pathology in the brain of APP\/PS1 transgenic mice via inhibiting \u03b2\/\u03b3-secretases activity and enhancing \u03b1-secretases. Curr Alzheimer Res 15(11):1045\u20131052","journal-title":"Curr Alzheimer Res"},{"key":"5054_CR94","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.exger.2017.02.004","volume":"91","author":"M Huang","year":"2017","unstructured":"Huang M, Jiang X, Liang Y, Liu Q, Chen S, Guo YI (2017) Berberine improves cognitive impairment by promoting autophagic clearance and inhibiting production of \u03b2-amyloid in APP\/tau\/PS1 mouse model of Alzheimer\u2019s disease. Exp Gerontol 91:25\u201333","journal-title":"Exp Gerontol"},{"key":"5054_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2202-12-125","volume":"12","author":"F Zhu","year":"2011","unstructured":"Zhu F, Wu F, Ma Y, Liu G, Li Z, Sun YA, Pei Z (2011) Decrease in the production of beta-amyloid by berberine inhibition of the expression of beta-secretase in HEK293 cells. BMC Neurosci 12:1\u20138","journal-title":"BMC Neurosci"},{"key":"5054_CR96","doi-asserted-by":"crossref","unstructured":"Zhang H, Zhao C, Cao G, Guo L, Zhang S, Liang Y, ... Zhang W (2017) Berberine modulates amyloid-\u03b2 peptide generation by activating AMP-activated protein kinase.\u00a0Neuropharmacology 125:408\u2013417","DOI":"10.1016\/j.neuropharm.2017.08.013"},{"key":"5054_CR97","doi-asserted-by":"crossref","unstructured":"Wang K, Chen Q, Wu N, Li Y, Zhang R, Wang J, ... Chen J (2019) Berberine ameliorates spatial learning memory impairment and modulates cholinergic anti-inflammatory pathway in diabetic rats.\u00a0Front Pharmacol 10:1003","DOI":"10.3389\/fphar.2019.01003"},{"key":"5054_CR98","doi-asserted-by":"crossref","unstructured":"Bhutada P, Mundhada Y, Bansod K, Tawari S, Patil S, Dixit P, ... Mundhada D (2011) Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes.\u00a0Behavioural Brain Res 220(1):30\u201341","DOI":"10.1016\/j.bbr.2011.01.022"},{"key":"5054_CR99","doi-asserted-by":"crossref","unstructured":"Kim MIA, Cho KH, Shin MS, Lee JM, Cho HS, Kim CJ, ... Yang HJ (2014) Berberine prevents nigrostriatal dopaminergic neuronal loss and suppresses hippocampal apoptosis in mice with Parkinson's disease. Int J Mol Med 33(4):870\u2013878","DOI":"10.3892\/ijmm.2014.1656"},{"issue":"6","key":"5054_CR100","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3390\/brainsci14060596","volume":"14","author":"HC Tseng","year":"2024","unstructured":"Tseng HC, Wang MH, Fang CH, Lin YW, Soung HS (2024) Neuroprotective potentials of berberine in rotenone-induced parkinson\u2019s disease-like motor symptoms in rats. Brain Sci 14(6):596","journal-title":"Brain Sci"},{"issue":"18","key":"5054_CR101","doi-asserted-by":"publisher","first-page":"8366","DOI":"10.1039\/D1FO01360B","volume":"12","author":"H Deng","year":"2021","unstructured":"Deng H, Ma Z (2021) Protective effects of berberine against MPTP-induced dopaminergic neuron injury through promoting autophagy in mice. Food Funct 12(18):8366\u20138375","journal-title":"Food Funct"},{"issue":"37","key":"5054_CR102","doi-asserted-by":"publisher","first-page":"3085","DOI":"10.2174\/1381612828666220922110551","volume":"28","author":"C Na","year":"2022","unstructured":"Na C, Wen-Wen C, Li W, Ao-Jia Z, Ting W (2022) Significant Role of Long Non-coding RNAs in Parkinson\u2019s Disease. Curr Pharm Des 28(37):3085\u20133094","journal-title":"Curr Pharm Des"},{"issue":"10","key":"5054_CR103","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1002\/kjm2.12241","volume":"36","author":"RX Xing","year":"2020","unstructured":"Xing RX, Li LG, Liu XW, Tian BX, Cheng Y (2020) Down regulation of miR-218, miR-124, and miR-144 relates to Parkinson\u2019s disease via activating NF-\u03baB signaling. Kaohsiung J Med Sci 36(10):786\u2013792","journal-title":"Kaohsiung J Med Sci"},{"key":"5054_CR104","doi-asserted-by":"publisher","first-page":"117637","DOI":"10.1016\/j.lfs.2020.117637","volume":"252","author":"N Zhang","year":"2020","unstructured":"Zhang N, Gao Y, Yu S, Sun X, Shen K (2020) Berberine attenuates A\u03b242-induced neuronal damage through regulating circHDAC9\/miR-142-5p axis in human neuronal cells. Life Sci 252:117637","journal-title":"Life Sci"},{"key":"5054_CR105","doi-asserted-by":"crossref","unstructured":"Gendy AM, Soubh A, Elnagar MR, Hamza E, Ahmed KA, Aglan A, ... El-Sadek HM (2023) New insights into the role of berberine against 3-nitropropionic acid-induced striatal neurotoxicity: Possible role of BDNF\u2013TrkB\u2013PI3K\/Akt and NF-\u03baB signaling.\u00a0Food Chem Toxicol 175:113721.","DOI":"10.1016\/j.fct.2023.113721"},{"issue":"4","key":"5054_CR106","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2174\/1389450115666140115113734","volume":"15","author":"J Gil-Mohapel","year":"2014","unstructured":"Gil-Mohapel J, Brocardo SP, Christie RB (2014) The role of oxidative stress in Huntington\u2019s disease: are antioxidants good therapeutic candidates? Current Drug Targets 15(4):454\u2013468","journal-title":"Current Drug Targets"},{"issue":"5","key":"5054_CR107","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1089\/rej.2017.1999","volume":"21","author":"X Liu","year":"2018","unstructured":"Liu X, Tian F, Wang S, Wang F, Xiong L (2018) Astrocyte autophagy flux protects neurons against oxygen-glucose deprivation and ischemic\/reperfusion injury. Rejuvenation Res 21(5):405\u2013415","journal-title":"Rejuvenation Res"},{"key":"5054_CR108","doi-asserted-by":"crossref","unstructured":"Xu ZQ, Zhang JJ, Kong N, Zhang GY, Ke P, Han T, ..., Liu C (2021) Autophagy is involved in neuroprotective effect of Alpha7 nicotinic acetylcholine receptor on ischemic stroke.\u00a0Front Pharmacol 12:676589","DOI":"10.3389\/fphar.2021.676589"},{"key":"5054_CR109","doi-asserted-by":"crossref","unstructured":"Liu YL, Guo T, Zhang YJ, Tang SC, Zhao XM, He HY, ..., Deng YH (2024) Berberine alleviates ischemic brain injury by enhancing autophagic flux via facilitation of TFEB nuclear translocation. Am J Chin Med 52(01):231\u2013252","DOI":"10.1142\/S0192415X24500101"},{"issue":"10","key":"5054_CR110","doi-asserted-by":"publisher","first-page":"e13489","DOI":"10.1371\/journal.pone.0013489","volume":"5","author":"X Ma","year":"2010","unstructured":"Ma X, Jiang Y, Wu A, Chen X, Pi R, Liu M, Liu Y (2010) Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL\/6 mice. PLoS ONE 5(10):e13489","journal-title":"PLoS ONE"},{"key":"5054_CR111","doi-asserted-by":"crossref","unstructured":"Tavaf MJ, Soltanmohammadi A, Zargarani S, Yazdanpanah E, Sadighimoghaddam B, Yousefi B, ..., Haghmorad D (2023) Berberine promotes immunological outcomes and decreases neuroinflammation in the experimental model of multiple sclerosis through the expansion of Treg and Th2 cells.\u00a0Immun Inflamm Disease 11(1):e766","DOI":"10.1002\/iid3.766"},{"issue":"3","key":"5054_CR112","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.bbrc.2017.06.142","volume":"490","author":"J Luo","year":"2017","unstructured":"Luo J, Chen R, Zeng S, Yu J, Jiang G, Wang L, Qin X (2017) The effects of berberine on a murine model of multiple sclerosis and the SPHK1\/S1P signaling pathway. Biochem Biophys Res Commun 490(3):927\u2013932","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"5054_CR113","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3233\/JHD-130052","volume":"2","author":"F Lin","year":"2013","unstructured":"Lin F, Qin ZH (2013) Degradation of misfolded proteins by autophagy: is it a strategy for Huntington\u2019s disease treatment? Journal of Huntington\u2019s disease 2(2):149\u2013157","journal-title":"Journal of Huntington's disease"},{"issue":"7","key":"5054_CR114","doi-asserted-by":"publisher","first-page":"e0134142","DOI":"10.1371\/journal.pone.0134142","volume":"10","author":"W Jiang","year":"2015","unstructured":"Jiang W, Wei W, Gaertig MA, Li S, Li XJ (2015) Therapeutic effect of berberine on Huntington\u2019s disease transgenic mouse model. PLoS ONE 10(7):e0134142","journal-title":"PLoS ONE"},{"key":"5054_CR115","doi-asserted-by":"crossref","unstructured":"Rusmini P, Cristofani R, Tedesco B, Ferrari V, Messi E, Piccolella M, ... Poletti A (2020) Enhanced clearance of neurotoxic misfolded proteins by the natural compound berberine and its derivatives.\u00a0Int J Mol Sci 21(10):3443","DOI":"10.3390\/ijms21103443"},{"issue":"13","key":"5054_CR116","doi-asserted-by":"publisher","first-page":"20909","DOI":"10.18632\/oncotarget.14959","volume":"8","author":"X La","year":"2017","unstructured":"La X, Zhang L, Li Z, Yang P, Wang Y (2017) Berberine-induced autophagic cell death by elevating GRP78 levels in cancer cells. Oncotarget 8(13):20909","journal-title":"Oncotarget"},{"issue":"9","key":"5054_CR117","doi-asserted-by":"publisher","first-page":"14914","DOI":"10.1002\/jcp.28325","volume":"234","author":"R Mohammadinejad","year":"2019","unstructured":"Mohammadinejad R, Ahmadi Z, Tavakol S, Ashrafizadeh M (2019) Berberine as a potential autophagy modulator. J Cell Physiol 234(9):14914\u201314926","journal-title":"J Cell Physiol"},{"issue":"11","key":"5054_CR118","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1080\/15384101.2015.1039365","volume":"14","author":"AM Cuervo","year":"2015","unstructured":"Cuervo AM, Zhang S (2015) Selective autophagy and Huntingtin: learning from disease. Cell Cycle 14(11):1617\u20131618","journal-title":"Cell Cycle"},{"issue":"7","key":"5054_CR119","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.drudis.2014.02.014","volume":"19","author":"CJ Cortes","year":"2014","unstructured":"Cortes CJ, La Spada AR (2014) The many faces of autophagy dysfunction in Huntington\u2019s disease: from mechanism to therapy. Drug Discovery Today 19(7):963\u2013971","journal-title":"Drug Discovery Today"},{"key":"5054_CR120","doi-asserted-by":"crossref","unstructured":"Ehrnhoefer DE, Martin DD, Schmidt ME, Qiu X, Ladha S, Caron NS, ... Hayden MR (2018) Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease.\u00a0Acta Neuropathologica Commun 6:1\u201316.","DOI":"10.1186\/s40478-018-0518-0"},{"issue":"4","key":"5054_CR121","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2174\/1389450115666140115113734","volume":"15","author":"J Gil-Mohapel","year":"2014","unstructured":"Gil-Mohapel J, Brocardo S, P., & R. Christie, B. (2014) The role of oxidative stress in Huntington\u2019s disease: are antioxidants good therapeutic candidates? Curr Drug Targets 15(4):454\u2013468","journal-title":"Curr Drug Targets"},{"issue":"1","key":"5054_CR122","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1750-3639.1999.tb00216.x","volume":"9","author":"SE Browne","year":"1999","unstructured":"Browne SE, Ferrante RJ, Beal MF (1999) Oxidative stress in Huntington\u2019s disease. Brain Pathol 9(1):147\u2013163","journal-title":"Brain Pathol"},{"issue":"11\u201312","key":"5054_CR123","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1089\/ars.2006.8.2061","volume":"8","author":"SE Browne","year":"2006","unstructured":"Browne SE, Beal MF (2006) Oxidative damage in Huntington\u2019s disease pathogenesis. Antioxid Redox Signal 8(11\u201312):2061\u20132073","journal-title":"Antioxid Redox Signal"},{"issue":"7","key":"5054_CR124","doi-asserted-by":"publisher","first-page":"10777","DOI":"10.18632\/oncotarget.14650","volume":"8","author":"JM Van Raamsdonk","year":"2017","unstructured":"Van Raamsdonk JM, Vega IE, Brundin P (2017) Oxidative stress in neurodegenerative disease: causation or association? Oncotarget 8(7):10777","journal-title":"Oncotarget"},{"key":"5054_CR125","doi-asserted-by":"crossref","unstructured":"Machiela E, Jeloka R, Caron NS, Mehta S, Schmidt ME, Baddeley HJ, ... Southwell AL (2020) The interaction of aging and cellular stress contributes to pathogenesis in mouse and human huntington disease neurons. Front Aging Neurosci 12:524369","DOI":"10.3389\/fnagi.2020.524369"},{"issue":"5","key":"5054_CR126","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ejps.2012.03.004","volume":"46","author":"YY Hsu","year":"2012","unstructured":"Hsu YY, Chen CS, Wu SN, Jong YJ, Lo YC (2012) Berberine activates Nrf2 nuclear translocation and protects against oxidative damage via a phosphatidylinositol 3-kinase\/Akt-dependent mechanism in NSC34 motor neuron-like cells. Eur J Pharm Sci 46(5):415\u2013425","journal-title":"Eur J Pharm Sci"},{"key":"5054_CR127","doi-asserted-by":"publisher","first-page":"67593","DOI":"10.1007\/s11356-021-15358-4","volume":"28","author":"AGS Shalkami","year":"2021","unstructured":"Shalkami AGS, Hassanein EH, Sayed AM, Mohamed WR, Khalaf MM, Hemeida RA (2021) Hepatoprotective effects of phytochemicals berberine and umbelliferone against methotrexate-induced hepatic intoxication: experimental studies and in silico evidence. Environ Sci Pollut Res 28:67593\u201367607","journal-title":"Environ Sci Pollut Res"},{"issue":"10","key":"5054_CR128","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.3390\/antiox12101883","volume":"12","author":"E Tian","year":"2023","unstructured":"Tian E, Sharma G, Dai C (2023) Neuroprotective properties of berberine: molecular mechanisms and clinical implications. Antioxidants 12(10):1883","journal-title":"Antioxidants"},{"key":"5054_CR129","doi-asserted-by":"crossref","unstructured":"Ma X, Chen Z, Wang L, Wang G, Wang Z, Dong X, ... Zhang Z (2018) The pathogenesis of diabetes mellitus by oxidative stress and inflammation: its inhibition by berberine.\u00a0Front Pharmacol 9:782","DOI":"10.3389\/fphar.2018.00782"},{"key":"5054_CR130","doi-asserted-by":"crossref","unstructured":"Wang Y, Liao J, Luo Y, Li M, Su X, Yu B, ... Lv X (2023) Berberine alleviates doxorubicin-induced myocardial injury and fibrosis by eliminating oxidative stress and mitochondrial damage via promoting nrf-2 pathway activation.\u00a0Int J Mol Sci 24(4):3257.","DOI":"10.3390\/ijms24043257"},{"issue":"1","key":"5054_CR131","doi-asserted-by":"publisher","first-page":"289264","DOI":"10.1155\/2014\/289264","volume":"2014","author":"Z Li","year":"2014","unstructured":"Li Z, Geng YN, Jiang JD, Kong WJ (2014) Antioxidant and anti-inflammatory activities of berberine in the treatment of diabetes mellitus. Evidence-Based Complement Alternat Med 2014(1):289264","journal-title":"Evidence-Based Complement Alternat Med"},{"key":"5054_CR132","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10059-013-2298-5","volume":"35","author":"J Bae","year":"2013","unstructured":"Bae J, Lee D, Kim YK, Gil M, Lee JY, Lee KJ (2013) Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1. Mol Cells 35:151\u2013157","journal-title":"Mol Cells"},{"issue":"12","key":"5054_CR133","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1097\/WNR.0b013e32832e34ee","volume":"20","author":"A Silvestroni","year":"2009","unstructured":"Silvestroni A, Faull RL, Strand AD, M\u00f6ller T (2009) Distinct neuroinflammatory profile in post-mortem human Huntington\u2019s disease. NeuroReport 20(12):1098\u20131103","journal-title":"NeuroReport"},{"key":"5054_CR134","doi-asserted-by":"crossref","unstructured":"Li X, Tong H, Xu S, Zhou G, Yang T, Yin S, ... Li S (2024) Neuroinflammatory Proteins in Huntington\u2019s Disease: Insights into Mechanisms, Diagnosis, and Therapeutic Implications.\u00a0Int J Mol Sci 25(21):11787","DOI":"10.3390\/ijms252111787"},{"issue":"3","key":"5054_CR135","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.phrs.2007.06.003","volume":"56","author":"CH Lee","year":"2007","unstructured":"Lee CH, Chen JC, Hsiang CY, Wu SL, Wu HC, Ho TY (2007) Berberine suppresses inflammatory agents-induced interleukin-1\u03b2 and tumor necrosis factor-\u03b1 productions via the inhibition of I\u03baB degradation in human lung cells. Pharmacol Res 56(3):193\u2013201","journal-title":"Pharmacol Res"},{"issue":"4","key":"5054_CR136","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1002\/ptr.8077","volume":"38","author":"F Shakeri","year":"2024","unstructured":"Shakeri F, Kiani S, Rahimi G, Boskabady MH (2024) Anti-inflammatory, antioxidant, and immunomodulatory effects of Berberis vulgaris and its constituent berberine, experimental and clinical, a review. Phytother Res 38(4):1882\u20131902","journal-title":"Phytother Res"},{"issue":"12","key":"5054_CR137","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.intimp.2011.08.008","volume":"11","author":"WC Lin","year":"2011","unstructured":"Lin WC, Lin JY (2011) Berberine down-regulates the Th1\/Th2 cytokine gene expression ratio in mouse primary splenocytes in the absence or presence of lipopolysaccharide in a preventive manner. Int Immunopharmacol 11(12):1984\u20131990","journal-title":"Int Immunopharmacol"},{"key":"5054_CR138","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fphar.2014.00230","volume":"5","author":"C Spatuzza","year":"2014","unstructured":"Spatuzza C, Postiglione L, Covelli B, Ricciardone M, Benvenuti C, Mondola P, Belfiore A (2014) Effects of berberine and red yeast on proinflammatory cytokines IL-6 and TNF-\u03b1 in peripheral blood mononuclear cells (PBMCs) of human subjects. Front Pharmacol 5:230","journal-title":"Front Pharmacol"},{"key":"5054_CR139","doi-asserted-by":"crossref","unstructured":"Bae YA, Cheon HG (2016) Activating transcription factor-3 induction is involved in the anti-inflammatory action of berberine in RAW264. 7 murine macrophages. Korean J Physiol Pharmacol: Off J Korean Physiol Soc Korean Soc Pharmacol 20(4):415","DOI":"10.4196\/kjpp.2016.20.4.415"},{"issue":"1","key":"5054_CR140","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2174\/1573397116666200907111303","volume":"17","author":"N Ghorbani","year":"2021","unstructured":"Ghorbani N, Sahebari M, Mahmoudi M, Rastin M, Zamani S, Zamani M (2021) Berberine inhibits the gene expression and production of proinflammatory cytokines by mononuclear cells in rheumatoid arthritis and healthy individuals. Curr Rheumatol Rev 17(1):113\u2013121","journal-title":"Curr Rheumatol Rev"},{"issue":"14","key":"5054_CR141","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1056\/NEJMra022366","volume":"348","author":"RM Friedlander","year":"2003","unstructured":"Friedlander RM (2003) Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 348(14):1365\u20131375","journal-title":"N Engl J Med"},{"key":"5054_CR142","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/978-3-7091-6284-2_13","volume":"7","author":"D Offen","year":"2000","unstructured":"Offen D, Elkon H, Melamed E (2000) Apoptosis as a general cell death pathway in neurodegenerative diseases. Adv Res Neurodegener 7:153\u2013166","journal-title":"Adv Res Neurodegener"},{"key":"5054_CR143","doi-asserted-by":"publisher","first-page":"1359136","DOI":"10.3389\/fimmu.2023.1359136","volume":"14","author":"C Soni","year":"2024","unstructured":"Soni C, Tyagi A, Wang X, Mathur R (2024) The molecular basis of programmed cell death and neuroinflammation in neurodegenerative diseases. Front Immunol 14:1359136","journal-title":"Front Immunol"},{"issue":"8","key":"5054_CR144","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1002\/ptr.6107","volume":"32","author":"X Lin","year":"2018","unstructured":"Lin X, Zhang N (2018) Berberine: Pathways to protect neurons. Phytother Res 32(8):1501\u20131510","journal-title":"Phytother Res"},{"key":"5054_CR145","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.brainres.2014.02.021","volume":"1557","author":"ENS Pires","year":"2014","unstructured":"Pires ENS, Frozza RL, Hoppe JB, de Melo Menezes B, Salbego CG (2014) Berberine was neuroprotective against an in vitro model of brain ischemia: survival and apoptosis pathways involved. Brain Res 1557:26\u201333","journal-title":"Brain Res"},{"key":"5054_CR146","doi-asserted-by":"crossref","unstructured":"Kim M, Shin MS, Lee JM, Cho HS, Kim CJ, Kim YJ, ... Jeon JW (2014) Inhibitory effects of isoquinoline alkaloid berberine on ischemia-induced apoptosis via activation of phosphoinositide 3-kinase\/protein kinase B signaling pathway.\u00a0Int Neurourol J 18(3):115","DOI":"10.5213\/inj.2014.18.3.115"},{"key":"5054_CR147","doi-asserted-by":"crossref","unstructured":"Cha JHJ, Frey AS, Alsdorf SA, Kerner JA, Kosinski CM, Mangiarini L, ... Young AB (1999) Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease.\u00a0Philosophical Transactions of the Royal Society of London. Series B: Biol Sci 354(1386):981\u2013989","DOI":"10.1098\/rstb.1999.0449"},{"key":"5054_CR148","doi-asserted-by":"publisher","first-page":"RRN1281","DOI":"10.1371\/currents.RRN1281","volume":"3","author":"T Renoir","year":"2011","unstructured":"Renoir T, Chevarin C, Lanfumey L, Hannan AJ (2011) Effect of enhanced voluntary physical exercise on brain levels of monoamines in Huntington disease mice. PLoS Currents 3:RRN1281","journal-title":"PLoS Currents"},{"key":"5054_CR149","unstructured":"Pearson SJ (1992)\u00a0The neurochemistry of Huntington's disease\u00a0(Doctoral dissertation, University of Nottingham)"},{"issue":"2","key":"5054_CR150","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/1570159X16666180302115032","volume":"17","author":"S Jamwal","year":"2019","unstructured":"Jamwal S, Kumar P (2019) Insight into the emerging role of striatal neurotransmitters in the pathophysiology of Parkinson\u2019s disease and Huntington\u2019s disease: a review. Curr Neuropharmacol 17(2):165\u2013175","journal-title":"Curr Neuropharmacol"},{"issue":"4","key":"5054_CR151","doi-asserted-by":"publisher","first-page":"616","DOI":"10.2174\/1386207324666210804122539","volume":"25","author":"R Mohi-Ud-Din","year":"2022","unstructured":"Mohi-Ud-Din R, Mir RH, Wani TU, Shah AJ, Banday N, Pottoo FH (2022) Berberine in the treatment of neurodegenerative diseases and nanotechnology enabled targeted delivery. Comb Chem High Throughput Screening 25(4):616\u2013633","journal-title":"Comb Chem High Throughput Screening"},{"issue":"2","key":"5054_CR152","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4196\/kjpp.2018.22.2.183","volume":"22","author":"B Lee","year":"2018","unstructured":"Lee B, Shim I, Lee H, Hahm DH (2018) Berberine alleviates symptoms of anxiety by enhancing dopamine expression in rats with post-traumatic stress disorder. Korean J Physiol Pharmacol 22(2):183\u2013192","journal-title":"Korean J Physiol Pharmacol"},{"issue":"1","key":"5054_CR153","first-page":"175062","volume":"2014","author":"J Hroudov\u00e1","year":"2014","unstructured":"Hroudov\u00e1 J, Singh N, Fi\u0161ar Z (2014) Mitochondrial dysfunctions in neurodegenerative diseases: relevance to Alzheimer\u2019s disease. Biomed Res Int 2014(1):175062","journal-title":"Biomed Res Int"},{"issue":"2","key":"5054_CR154","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3390\/antiox6020025","volume":"6","author":"J Gao","year":"2017","unstructured":"Gao J, Wang L, Liu J, Xie F, Su B, Wang X (2017) Abnormalities of mitochondrial dynamics in neurodegenerative diseases. Antioxidants 6(2):25","journal-title":"Antioxidants"},{"key":"5054_CR155","unstructured":"R\u00f3na-V\u00f6r\u00f6s K (2015) The role of axonal transport and mitochondrial dysfunction in neurodegeneration-focusing on Huntington's disease\u00a0(Doctoral dissertation, Szegedi Tudomanyegyetem (Hungary))"},{"key":"5054_CR156","doi-asserted-by":"publisher","first-page":"982145","DOI":"10.3389\/fendo.2022.982145","volume":"13","author":"X Fang","year":"2022","unstructured":"Fang X, Wu H, Wei J, Miao R, Zhang Y, Tian J (2022) Research progress on the pharmacological effects of berberine targeting mitochondria. Front Endocrinol 13:982145","journal-title":"Front Endocrinol"},{"issue":"1","key":"5054_CR157","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3390\/ijms25010219","volume":"25","author":"JH Um","year":"2023","unstructured":"Um JH, Lee KM, Kim YY, Lee DY, Kim E, Kim DH, Yun J (2023) Berberine induces mitophagy through adenosine monophosphate-activated protein kinase and ameliorates mitochondrial dysfunction in PINK1 knockout mouse embryonic fibroblasts. Int J Mol Sci 25(1):219","journal-title":"Int J Mol Sci"},{"issue":"6","key":"5054_CR158","doi-asserted-by":"publisher","first-page":"5896","DOI":"10.3390\/ijms24065896","volume":"24","author":"C Wang","year":"2023","unstructured":"Wang C, Zou Q, Pu Y, Cai Z, Tang Y (2023) Berberine Rescues D-Ribose-Induced Alzheimer\u2018s Pathology via Promoting Mitophagy. Int J Mol Sci 24(6):5896","journal-title":"Int J Mol Sci"},{"key":"5054_CR159","doi-asserted-by":"crossref","unstructured":"Zhu N, Cao X, Hao P, Zhang Y, Chen Y, Zhang J, ... Li L (2020) Berberine attenuates mitochondrial dysfunction by inducing autophagic flux in myocardial hypoxia\/reoxygenation injury.\u00a0Cell Stress Chaperones\u00a025:417\u2013426.","DOI":"10.1007\/s12192-020-01081-5"},{"issue":"8","key":"5054_CR160","first-page":"14513","volume":"8","author":"Y Wang","year":"2015","unstructured":"Wang Y, Liu J, Ma A, Chen Y (2015) Cardioprotective effect of berberine against myocardial ischemia\/reperfusion injury via attenuating mitochondrial dysfunction and apoptosis. Int J Clin Exp Med 8(8):14513","journal-title":"Int J Clin Exp Med"},{"issue":"8","key":"5054_CR161","doi-asserted-by":"publisher","first-page":"890","DOI":"10.2174\/1389450117666160201105645","volume":"17","author":"C Marinangeli","year":"2016","unstructured":"Marinangeli C, Didier S, Vingtdeux V (2016) AMPK in neurodegenerative diseases: implications and therapeutic perspectives. Curr Drug Targets 17(8):890\u2013907","journal-title":"Curr Drug Targets"},{"key":"5054_CR162","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.1007\/s00018-012-1025-2","volume":"69","author":"TC Ju","year":"2012","unstructured":"Ju TC, Lin YS, Chern Y (2012) Energy dysfunction in Huntington\u2019s disease: insights from PGC-1\u03b1, AMPK, and CKB. Cell Mol Life Sci 69:4107\u20134120","journal-title":"Cell Mol Life Sci"},{"key":"5054_CR163","doi-asserted-by":"publisher","unstructured":"Domise M, Vingtdeux V (2016) AMPK in neurodegenerative diseases. In: AMP-activated protein kinase. Academic Press,\u00a0pp 153\u2013177. https:\/\/doi.org\/10.1016\/B978-0-12-802922-8.00012-6","DOI":"10.1016\/B978-0-12-802922-8.00012-6"},{"key":"5054_CR164","doi-asserted-by":"crossref","unstructured":"V\u00e1zquez-Manrique RP, Farina F, Cambon K, Dolores Sequedo M, Parker AJ, Mill\u00e1n JM, ... Neri C (2016) AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease.\u00a0Human Mol Genet 25(6):1043\u20131058","DOI":"10.1093\/hmg\/ddv513"},{"key":"5054_CR165","doi-asserted-by":"crossref","unstructured":"Ju TC, Chen HM, Chen YC, Chang CP, Chang C, Chern Y (2014) AMPK-\u03b11 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.\u00a0Biochimica et Biophysica Acta (BBA)-Mol Basis of Disease 1842(9):1668\u20131680.","DOI":"10.1016\/j.bbadis.2014.06.012"},{"key":"5054_CR166","doi-asserted-by":"crossref","unstructured":"Qin S, Tang H, Li W, Gong Y, Li S, Huang J, ... Xu Z (2020) AMPK and its activator berberine in the treatment of neurodegenerative diseases.\u00a0Curr Pharm Design\u00a026(39):5054\u20135066","DOI":"10.2174\/1381612826666200523172334"},{"issue":"9","key":"5054_CR167","doi-asserted-by":"publisher","first-page":"e25436","DOI":"10.1371\/journal.pone.0025436","volume":"6","author":"Q Wang","year":"2011","unstructured":"Wang Q, Zhang M, Liang B, Shirwany N, Zhu Y, Zou MH (2011) Activation of AMP-activated protein kinase is required for berberine-induced reduction of atherosclerosis in mice: the role of uncoupling protein 2. PLoS ONE 6(9):e25436","journal-title":"PLoS ONE"},{"issue":"11","key":"5054_CR168","doi-asserted-by":"publisher","first-page":"e15420","DOI":"10.1371\/journal.pone.0015420","volume":"5","author":"Y Han","year":"2010","unstructured":"Han Y, Wang Q, Song P, Zhu Y, Zou MH (2010) Redox regulation of the AMP-activated protein kinase. PLoS ONE 5(11):e15420","journal-title":"PLoS ONE"},{"key":"5054_CR169","doi-asserted-by":"crossref","unstructured":"Lee YS, Kim WS, Kim KH, Yoon MJ, Cho HJ, Shen Y, ... Kim JB (2006) Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states.\u00a0Diabetes 55(8):2256\u20132264.","DOI":"10.2337\/db06-0006"},{"key":"5054_CR170","doi-asserted-by":"crossref","unstructured":"Jeong HW, Hsu KC, Lee JW, Ham M, Huh JY, Shin HJ, ... Kim JB (2009) Berberine suppresses proinflammatory responses through AMPK activation in macrophages.\u00a0Am J Physiol-Endocrinol Metab 296(4):E955-E964","DOI":"10.1152\/ajpendo.90599.2008"},{"key":"5054_CR171","doi-asserted-by":"crossref","unstructured":"Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS, Lee MR, ... Kim JB (2009) Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity.\u00a0Am J Physiol-Endocrinol Metab 296(4):E812-E819","DOI":"10.1152\/ajpendo.90710.2008"},{"key":"5054_CR172","doi-asserted-by":"crossref","unstructured":"Qiang X, Xu L, Zhang M, Zhang P, Wang Y, Wang Y, ... Zhang Y (2016) Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.\u00a0Biochem Biophys Res Commun 472(4):603\u2013609","DOI":"10.1016\/j.bbrc.2016.03.019"},{"key":"5054_CR173","doi-asserted-by":"publisher","unstructured":"Koenig A, Lewis M, Wald J, Li S, Varoglu M, Dai J, Sankoh AJ, Paumier K, Doherty J, Quirk M (2024) Dalzanemdor (SAGE\u2010718), a novel, investigational N\u2010methyl\u2010D\u2010aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose\u2010finding studies in healthy participants and an open\u2010label study in participants with Huntington\u2019s disease. Clin Transl Sci17(7). https:\/\/doi.org\/10.1111\/cts.13852","DOI":"10.1111\/cts.13852"},{"key":"5054_CR174","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16235","author":"JT Beckley","year":"2023","unstructured":"Beckley JT, Aman TK, Ackley MA, Kazdoba TM, Lewis MC, Smith AC, Farley BJ, Dai J, Deats W, Hoffmann E, Robichaud AJ, Doherty JJ, Quirk MC (2023) Pharmacological characterization of SAGE-718, a novel NMDA receptor positive allosteric modulator. Br J Pharmacol. https:\/\/doi.org\/10.1111\/bph.16235","journal-title":"Br J Pharmacol"},{"issue":"11","key":"5054_CR175","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1111\/JCMM.12604","volume":"19","author":"F Squitieri","year":"2015","unstructured":"Squitieri F, Di Pardo A, Favellato M, Amico E, Maglione V, Frati L (2015) Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model. J Cell Mol Med 19(11):2540\u20132548. https:\/\/doi.org\/10.1111\/JCMM.12604","journal-title":"J Cell Mol Med"},{"key":"5054_CR176","doi-asserted-by":"publisher","unstructured":"Geva M, Akinc Abdulhayoglu D, Wang SM, Gershoni-Emek N, Boulanger B, Goldberg YP, Su T-P, Hayden MR (2022) J11\u2005Pridopidine exerts beneficial effects in preclinical models and in clinical trials via activation of the sigma-1 receptor, in a biphasic manner. https:\/\/doi.org\/10.1136\/jnnp-2022-ehdn.261","DOI":"10.1136\/jnnp-2022-ehdn.261"},{"key":"5054_CR177","doi-asserted-by":"publisher","unstructured":"Simmons DA, Knowles JK, Belichenko NP, Banerjee G, Finkle C, Massa SM, Longo FM (2014) A Small Molecule p75NTR Ligand, LM11A-31, Reverses Cholinergic Neurite Dystrophy in Alzheimer\u2019s Disease Mouse Models with Mid- to Late-Stage Disease Progression. PLOS ONE 9(8). https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0102136","DOI":"10.1371\/JOURNAL.PONE.0102136"},{"key":"5054_CR178","doi-asserted-by":"publisher","unstructured":"Nguyen T-VV, Rh C, Calderon K, Garcia FG, Zbesko JC, Frye JBSG, Becktel DA, Yang TT, Tavera-Garcia MA, Morrison HW, Schnellmann RG, Longo FM, Doyle KP (2021) Post-stroke administration of the p75 neurotrophin receptor modulator, LM11A-31, attenuates chronic changes in brain metabolism, increases neurotransmitter levels, and improves recovery. bioRxiv. https:\/\/doi.org\/10.1101\/2021.04.30.442181","DOI":"10.1101\/2021.04.30.442181"},{"issue":"1","key":"5054_CR179","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/J.1552-4604.1994.TB03964.X","volume":"34","author":"T Uematsu","year":"1994","unstructured":"Uematsu T, Nagashima S, Inaba H, Mizuno A, Kosuge K, Nakashima M (1994) Pharmacokinetic and pharmacodynamic profiles of CS-518, a selective, long-lasting thromboxane synthase inhibitor, after single and multiple oral administration to healthy volunteers. J Clin Pharmacol 34(1):41\u201347. https:\/\/doi.org\/10.1002\/J.1552-4604.1994.TB03964.X","journal-title":"J Clin Pharmacol"},{"key":"5054_CR180","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2024.42.4_suppl.124","author":"A Azad","year":"2024","unstructured":"Azad A, Gurney H, Underhill C, Horvath LE, Voskoboynik M, Li X, King I, Shao L, Dai Y, Perabo F (2024) Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor activity in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2024.42.4_suppl.124","journal-title":"J Clin Oncol"},{"key":"5054_CR181","doi-asserted-by":"publisher","unstructured":"Stimming EF, Fung V, Testa CM, Kostyk SK, Ross CA, Samii A, Geschwind MD, Hall D, Dayalu P, Lonser RR, Elder B, Larson PS, Cooper DL, Clarkin M, Ali TM, Dolmetsch RE (2022) J05\u2005Interim results from cohort 1 of the double-blind, dose-escalation phase I\/II clinical trial of amt-130 (HD-genetrx-1) for early-stage huntington\u2019s disease (HD). https:\/\/doi.org\/10.1136\/jnnp-2022-ehdn.255","DOI":"10.1136\/jnnp-2022-ehdn.255"},{"issue":"10","key":"5054_CR182","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1517\/17425255.2013.802772","volume":"9","author":"S Alqahtani","year":"2013","unstructured":"Alqahtani S, Mohamed LA, Kaddoumi A (2013) Experimental models for predicting drug absorption and metabolism. Expert Opin Drug Metab Toxicol 9(10):1241\u20131254. https:\/\/doi.org\/10.1517\/17425255.2013.802772","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"5054_CR183","doi-asserted-by":"publisher","unstructured":"Keller CG, Shin Y, Monteys AM, Renaud NA, Beibel M., Teider N, Peters T, Faller TH, St-Cyr S, Knehr J., Roma G, Reyes A, Hild M, Lukashev D, Theil D, Dales NA, Cha J-H, Borowsky B, Dolmetsch RE, \u2026 Sivasankaran R (2022) An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion. Nat Commun 13(1). https:\/\/doi.org\/10.1038\/s41467-022-28653-6","DOI":"10.1038\/s41467-022-28653-6"},{"key":"5054_CR184","doi-asserted-by":"publisher","unstructured":"Garrido B, Ribeiro JA, Palavra F (2023) Branaplam as a Promising Splicing Modulator: From Spinal Muscular Atrophy to Huntington\u2019s Disease. Sinapse 23(2):82\u201391. https:\/\/doi.org\/10.46531\/sinapse\/ar\/230005\/2023","DOI":"10.46531\/sinapse\/ar\/230005\/2023"},{"issue":"2","key":"5054_CR185","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3233\/JHD-150180","volume":"5","author":"V Billes","year":"2016","unstructured":"Billes V, Kov\u00e1cs T, Hotzi B, Manz\u00e9ger A, Tagscherer K, Koml\u00f3s M, Tarn\u00f3ci A, Padar Z, Erd\u0151s A, Bjelik A, L\u00e9gr\u00e1di \u00c1, Gulya K, Guly\u00e1s B, Guly\u00e1s B, Guly\u00e1s B, Vellai T (2016) AUTEN-67 (Autophagy Enhancer-67) Hampers the Progression of Neurodegenerative Symptoms in a Drosophila model of Huntington\u2019s Disease. J Huntington\u2019s Disease 5(2):133\u2013147. https:\/\/doi.org\/10.3233\/JHD-150180","journal-title":"J Huntington\u2019s Disease"},{"key":"5054_CR186","doi-asserted-by":"publisher","unstructured":"Bahat A, Itzhaki E, Weiss B, Tolmasov M, Tsoory M, Kuperman Y, Brandis A, Shurrush KA, Dikstein R (2023) Lowering mutant huntingtin by small molecules relieves Huntington\u2019s disease symptoms and progression. bioRxiv. https:\/\/doi.org\/10.1101\/2023.11.21.568060","DOI":"10.1101\/2023.11.21.568060"},{"key":"5054_CR187","doi-asserted-by":"publisher","unstructured":"Yamamoto Y, Sanwald Ducray P, Bj\u00f6rnsson MA, Smart K, Grimsey P, Vatakuti S, Portron A, Massonnet B, Norris DA (2023) Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma. CPT: Pharmacometrics Syst Pharmacology. https:\/\/doi.org\/10.1002\/psp4.13001","DOI":"10.1002\/psp4.13001"},{"issue":"6","key":"5054_CR188","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1097\/WNF.0B013E318166DA60","volume":"31","author":"A Fasano","year":"2008","unstructured":"Fasano A, Cadeddu F, Guidubaldi A, Piano C, Soleti F, Zinzi P, Bentivoglio AR (2008) The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol 31(6):313\u2013318. https:\/\/doi.org\/10.1097\/WNF.0B013E318166DA60","journal-title":"Clin Neuropharmacol"},{"key":"5054_CR189","unstructured":"Paleacu D (2007) Tetrabenazine in the treatment of Huntington\u2019s disease. Neuropsychiatr Dis Treat 3(5):545\u2013551.\u00a0Retrieved May 10, 2025, from\u00a0https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2656291"},{"key":"5054_CR190","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1517\/14656560903386292","volume":"10","author":"A Fasano","year":"2009","unstructured":"Fasano A, Bentivoglio AR (2009) Tetrabenazine. Expert Opin Pharmacother 10:2883\u20132896. https:\/\/doi.org\/10.1517\/14656560903386292","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"5054_CR191","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/NMT-2018-0040","volume":"9","author":"A Richard","year":"2019","unstructured":"Richard A, Frank S (2019) Deutetrabenazine in the treatment of Huntington\u2019s disease. Neurodegenerative Disease Management 9(1):31\u201337. https:\/\/doi.org\/10.2217\/NMT-2018-0040","journal-title":"Neurodegenerative Disease Management"},{"key":"5054_CR192","doi-asserted-by":"publisher","unstructured":"Reinfeld HB (2024) Huntington Disease Treated with Austedo (Deutetrabenazine). https:\/\/doi.org\/10.37191\/mapsci-2582-4333-6(3)-158","DOI":"10.37191\/mapsci-2582-4333-6(3)-158"},{"issue":"5","key":"5054_CR193","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1017\/s1092852924001871","volume":"29","author":"EF Stimming","year":"2024","unstructured":"Stimming EF, Claassen DO, Kayson E, Goldstein J, Hinton SC, Klepitskaya O, Zhang H, Liang G, Haubenberger D (2024) Sustained improvements in chorea associated with huntington disease with once-daily valbenazine: interim results from a long-term open-label study. CNS Spectr 29(5):513\u2013514. https:\/\/doi.org\/10.1017\/s1092852924001871","journal-title":"CNS Spectr"},{"key":"5054_CR194","doi-asserted-by":"publisher","unstructured":"Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington\u2019s disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. (2023). Lancet Neurol 22(6):494\u2013504. https:\/\/doi.org\/10.1016\/s1474-4422(23)00127-8","DOI":"10.1016\/s1474-4422(23)00127-8"},{"issue":"2","key":"5054_CR195","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1097\/YIC.0B013E3283407775","volume":"26","author":"TG Johnston","year":"2011","unstructured":"Johnston TG (2011) Risperidone long-acting injection and Huntington\u2019s disease: case series with significant psychiatric and behavioural symptoms. Int Clin Psychopharmacol 26(2):114\u2013119. https:\/\/doi.org\/10.1097\/YIC.0B013E3283407775","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"5054_CR196","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10401230701844802","volume":"20","author":"K Duff","year":"2008","unstructured":"Duff K, Beglinger LJ, O\u2019Rourke ME, Nopoulos P, Paulson HL, Paulsen JS (2008) Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington\u2019s disease. Ann Clin Psychiatry 20(1):1\u20133. https:\/\/doi.org\/10.1080\/10401230701844802","journal-title":"Ann Clin Psychiatry"},{"key":"5054_CR197","unstructured":"Cankurtaran ES, \u00d6zalp E, Soyg\u00fcr H, Cakir A (2006) Clinical experience with risperidone and memantine in the treatment of Huntington\u2019s disease. J Nat Med Assoc 98(8):1353\u20131355. https:\/\/pubmed.ncbi.nlm.nih.gov\/16916137\/"},{"issue":"11","key":"5054_CR198","doi-asserted-by":"publisher","first-page":"22558","DOI":"10.3390\/IJMS141122558","volume":"14","author":"EC Lauterbach","year":"2013","unstructured":"Lauterbach EC (2013) Neuroprotective effects of psychotropic drugs in Huntington\u2019s disease. Int J Mol Sci 14(11):22558\u201322603. https:\/\/doi.org\/10.3390\/IJMS141122558","journal-title":"Int J Mol Sci"},{"issue":"4","key":"5054_CR199","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1097\/00002826-198908000-00010","volume":"12","author":"FO Walker","year":"1989","unstructured":"Walker FO, Hunt V (1989) An open label trial of dextromethorphan in Huntington\u2019s disease. Clin Neuropharmacol 12(4):322\u2013330. https:\/\/doi.org\/10.1097\/00002826-198908000-00010","journal-title":"Clin Neuropharmacol"},{"key":"5054_CR200","doi-asserted-by":"publisher","unstructured":"Furr-Stimming E, Abdollah Zadegan S, Patino Murillas J, Dongarwar D, Rocha NP (2024) A pilot study to evaluate the efficacy of dextromethorphan\/quinidine in treating irritability in Huntington\u2019s Disease (P6\u20133.008). Neurology. https:\/\/doi.org\/10.1212\/wnl.0000000000208191","DOI":"10.1212\/wnl.0000000000208191"},{"key":"5054_CR201","unstructured":"Mart\u00ednez Triguero M (1993) Literature review on fenofibrate. An Med Interna\u00a010(4):195.\u00a0Retrieved\u00a0May 10, 2025, from\u00a0https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8513089"},{"key":"5054_CR202","unstructured":"Polymeropoulos M, Federoff HJ, Su X (2014) Treating neurodegenerative disease with fenofibrate and analogs thereof.\u00a0Patent WO2015042286A1. Retrieved\u00a0May 10, 2025, from\u00a0https:\/\/patents.google.com\/patent\/WO2015042286A1\/en"},{"key":"5054_CR203","unstructured":"Polymeropoulos M, Federoff HJ, Su X (2014) Traitement d\u2019une maladie neurod\u00e9g\u00e9n\u00e9rative au moyen de f\u00e9nofibrate et de ses analogues. https:\/\/patents.google.com\/patent\/WO2015042286A1\/fr"},{"key":"5054_CR204","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/ELIFE.38744","volume":"7","author":"I Arnoux","year":"2018","unstructured":"Arnoux I, Willam M, Griesche N, Krummeich J, Watari H, Offermann N, Weber S, Dey PN et al (2018) Metformin reverses early cortical network dysfunction and behavior changes in Huntington\u2019s disease. eLife 7:1\u201332. https:\/\/doi.org\/10.7554\/ELIFE.38744","journal-title":"eLife"},{"issue":"3","key":"5054_CR205","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1515\/REVNEURO-2019-0072","volume":"31","author":"BL Tang","year":"2020","unstructured":"Tang BL (2020) Could metformin be therapeutically useful in Huntington\u2019s disease? Rev Neurosci 31(3):297\u2013317. https:\/\/doi.org\/10.1515\/REVNEURO-2019-0072","journal-title":"Rev Neurosci"},{"issue":"4","key":"5054_CR206","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/S12017-016-8412-Z","volume":"18","author":"J Jin","year":"2016","unstructured":"Jin J, Gu H, Anders NM, Ren T, Ren T, Jiang M, Tao M, Peng Q, Rudek MA, Duan W (2016) Metformin protects cells from mutant huntingtin toxicity through activation of AMPK and modulation of mitochondrial dynamics. NeuroMol Med 18(4):581\u2013592. https:\/\/doi.org\/10.1007\/S12017-016-8412-Z","journal-title":"NeuroMol Med"},{"issue":"52","key":"5054_CR207","doi-asserted-by":"publisher","first-page":"e41073","DOI":"10.1097\/md.0000000000041073","volume":"103","author":"M Alharthi","year":"2024","unstructured":"Alharthi M (2024) A narrative review of phase III and IV clinical trials for the pharmacological treatment of Huntington\u2019s disease in adults. Medicine 103(52):e41073. https:\/\/doi.org\/10.1097\/md.0000000000041073","journal-title":"Medicine"},{"issue":"12","key":"5054_CR208","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.3390\/metabo12121225","volume":"12","author":"KE Anderson","year":"2022","unstructured":"Anderson KE, Stevenson M, Varghese RS, Hebron M, Koppel E, McCartin MC, Kuprewicz R, Matar S, Ferrante D, Moussa C (2022) Alteration of autophagy and glial activity in nilotinib-treated huntington\u2019s disease patients. Metabolites 12(12):1225. https:\/\/doi.org\/10.3390\/metabo12121225","journal-title":"Metabolites"},{"issue":"3","key":"5054_CR209","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s44321-023-00020-y","volume":"16","author":"A Bahat","year":"2024","unstructured":"Bahat A, Itzhaki E, Weiss B, Tolmasov M, Tsoory M, Kuperman Y, Brandis A, Shurrush KA, Dikstein R (2024) Lowering mutant huntingtin by small molecules relieves Huntington\u2019s disease symptoms and progression. EMBO Mol Med 16(3):523\u2013546. https:\/\/doi.org\/10.1038\/s44321-023-00020-y","journal-title":"EMBO Mol Med"},{"key":"5054_CR210","doi-asserted-by":"publisher","unstructured":"Adanyeguh IM, Rinaldi D, Henry P-G, Caillet S, Valabregue R, Durr A, Mochel F (2014) N04 Anaplerotic Therapy Using Triheptanoin Improves Brain Energy Metabolism In Patients With Huntington Disease. J Neurol Neurosurg Psychiatr 85. https:\/\/doi.org\/10.1136\/JNNP-2014-309032.296","DOI":"10.1136\/JNNP-2014-309032.296"},{"issue":"5","key":"5054_CR211","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1212\/WNL.0000000000001214","volume":"84","author":"IM Adanyeguh","year":"2015","unstructured":"Adanyeguh IM, Rinaldi D, Henry P-G, Caillet S, Valabregue R, D\u00fcrr A, Mochel F (2015) Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology 84(5):490\u2013495. https:\/\/doi.org\/10.1212\/WNL.0000000000001214","journal-title":"Neurology"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05054-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12035-025-05054-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-025-05054-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:05:17Z","timestamp":1760036717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12035-025-05054-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":211,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["5054"],"URL":"https:\/\/doi.org\/10.1007\/s12035-025-05054-6","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"9 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this study is a review of existing literature and does not involve human or animal subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}